Amarin Corporation develops and commercializes high-quality omega-3 fatty acid ingredients derived from microalgae and fish oil for human health, pet care, and aquaculture sectors globally.
The company possesses a unique technology platform with patented omega-3 extraction methods that offer long-term differentiation in a crowded supplement market. Recent cash flow from operations turned positive at $6.7M and ending cash balances reached $134.9M, indicating improved liquidity management despite the net loss. Successful penetration of new markets or product approvals could unlock significant value given the high barriers to entry in the pharmaceutical-grade omega-3 space.
Revenue has declined for three consecutive years from $369.2M in 2022 to $213.6M in 2025, signaling a structural decline in demand or market share loss. The substantial retained earnings deficit of -$1.71B and persistent operating losses suggest the business model is struggling to achieve sustainable profitability without major restructuring. Inventory levels of $195.9M relative to current assets may indicate slowing sales velocity or write-down risks if products do not move quickly enough.
Amarin Corporation plc is a global developer of omega-3 fatty acids derived from microalgae and fish oil, serving markets in North America, Europe, Asia, and Latin America. The company's key products include prescription-grade omega-3s for cardiovascular health, over-the-counter supplements, and specialized formulations for pet nutrition and aquaculture feed.
Despite a notable improvement in net loss narrowing from -$82.2M in 2024 to -$38.8M in 2025, revenue continued its downward trend, falling to $213.6M. Operating expenses of $171.0M significantly outpaced gross profit of $120.9M, resulting in an operating loss of -$50.2M, suggesting ongoing pressure on margins and the need for cost rationalization.
The global omega-3 fatty acid market is competitive but heavily regulated, with demand driven by growing consumer awareness of cardiovascular health benefits. Microalgae-based production offers a sustainable alternative to depleting fish stocks, which aligns with increasing ESG investment trends and regulatory push for sustainable sourcing. Key players compete on purity levels, certification standards, and the ability to secure long-term supply contracts with major pharmaceutical companies.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $369.2M | $306.9M | $228.6M | $213.6M |
| Cost of Revenue | $126.7M | $141.4M | $147.2M | $92.8M |
| Gross Profit | $242.5M | $165.5M | $81.4M | $120.9M |
| Operating Expenses | $348.4M | $233.1M | $173.2M | $171.0M |
| Operating Income | $-105.9M | $-67.6M | $-91.8M | $-50.2M |
| R&D | $30.4M | $22.2M | $20.9M | $19.8M |
| G&A | $304.4M | $199.9M | $38.3M | $43.8M |
| Stock-Based Comp | $26.2M | $15.6M | $17.7M | $13.9M |
| Depreciation | $600.0K | $200.0K | $100.0K | — |
| Amortization | $2.5M | $2.8M | $2.9M | $3.0M |
| Other OpEx | $13.5M | $11.0M | $114.0M | $107.5M |
| Non-Operating Income | $2.1M | $13.9M | $14.6M | $14.1M |
| Interest Expense | $15.0K | $8.0K | $7.0K | $7.0K |
| Interest Income | $2.8M | $11.9M | $13.4M | $10.9M |
| Pre-Tax Income | $-103.8M | $-53.7M | $-77.2M | $-36.0M |
| Income Tax | $2.0M | $5.4M | $5.0M | $2.8M |
| Continuing Ops | $-105.8M | $-59.1M | $-82.2M | $-38.8M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-105.8M | $-59.1M | $-82.2M | $-38.8M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-105.8M | $-59.1M | $-82.2M | $-38.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $689.1M | $725.0M | $595.4M | $649.9M |
| Cash & Equivalents | $217.7M | $199.3M | $121.0M | $134.7M |
| Marketable Securities | $91.7M | $121.4M | $173.2M | $167.9M |
| Accounts Receivable | $131.0M | $133.6M | $122.3M | $126.8M |
| Inventory | $228.7M | $258.6M | $166.0M | $195.9M |
| Prepaid Expenses | $19.5M | $11.6M | $12.6M | $24.4M |
| Other Current Assets | $523.0K | $525.0K | $300.0K | $201.0K |
| Long-Term Assets | $197.1M | $106.7M | $90.0M | $20.9M |
| PP&E (Net) | $874.0K | $114.0K | $16.0K | $12.0K |
| Operating Leases | $9.1M | $8.3M | $7.6M | $6.5M |
| LT Investments | $1.3M | — | — | — |
| Other LT Assets | $185.9M | $98.3M | $82.3M | $14.4M |
| Total Assets | $886.2M | $831.7M | $685.3M | $670.8M |
| Current Liabilities | $259.5M | $259.3M | $179.9M | $194.5M |
| Accounts Payable | $64.6M | $52.8M | $40.4M | $45.4M |
| Current Leases | $1.6M | $1.9M | $2.0M | $2.1M |
| Deferred Revenue | $2.2M | $2.3M | — | — |
| Other Current Liab | $191.1M | $202.3M | $137.6M | $147.0M |
| Long-Term Liabilities | $31.4M | $20.3M | $19.2M | $17.0M |
| LT Operating Leases | $10.0M | $8.7M | $7.7M | $6.1M |
| Other LT Liab | $8.2M | $9.1M | $11.5M | $11.0M |
| Total Liabilities | $290.8M | $279.6M | $199.2M | $211.5M |
| Shareholders' Equity | $595.3M | $552.1M | $486.2M | $459.3M |
| Paid-In Capital | $1.89B | $1.90B | $1.91B | $1.92B |
| Retained Earnings | $-1.53B | $-1.59B | $-1.67B | $-1.71B |
| Treasury Stock | $61.8M | $63.8M | $65.3M | $67.4M |
| Total L&E | $886.2M | $831.7M | $685.3M | $670.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-105.8M | $-59.1M | $-82.2M | $-38.8M |
| Non-Cash Adjustments | $28.7M | $137.7M | $246.7M | $50.8M |
| Working Capital Changes | $-103.0M | $-71.7M | $-195.6M | $-5.3M |
| Cash from Operations | $-180.1M | $6.9M | $-31.0M | $6.7M |
| Cash from Investing | $175.3M | $-25.5M | $-46.0M | $8.8M |
| Cash from Financing | $-379.0K | $230.0K | $-1.4M | $-2.0M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-5.2M | $-18.4M | $-78.4M | $13.5M |
| Beginning Cash | $223.4M | $218.2M | $199.8M | $121.3M |
| Ending Cash | $218.2M | $199.8M | $121.3M | $134.9M |
The company's revenue is primarily driven by the sale of omega-3 ingredients to contract manufacturers in the pharmaceutical and dietary supplement industries, alongside direct sales of finished omega-3 products for human consumption. Significant revenue streams also come from supplying high-purity fish oil and microalgae-based omega-3s to the pet food industry and aquaculture operations.
The company faces significant volatility due to fluctuating raw material costs and supply chain disruptions affecting fish oil availability. Regulatory changes in key markets like the US or EU regarding dietary supplements could impact sales of their over-the-counter product lines. High levels of accumulated retained earnings deficit indicate persistent profitability challenges that may limit future growth capital unless operational efficiency improves drastically.
Amarin holds a proprietary portfolio of patented technologies for isolating and purifying omega-3s, creating barriers to entry against competitors. Its vertically integrated supply chain from algae cultivation to final product formulation ensures consistent quality and sustainability credentials that appeal to eco-conscious consumers and formulators. The company's established global distribution network and regulatory approvals in multiple jurisdictions provide a strong foothold in protected markets.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.